Orlistat, a new lipase inhibitor for the management of obesity

Pharmacotherapy. 2000 Mar;20(3):270-9. doi: 10.1592/phco.


Orlistat, a weight-loss agent with a novel mechanism of action, recently was approved by the Food and Drug Administration for the treatment of obesity. It inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease systemic absorption of dietary fat. In several trials lasting up to 2 years, orlistat was more effective than diet alone for weight reduction and maintenance of lost weight. Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations. The major adverse effects are gastrointestinal, usually occur early in therapy, and tend to decrease with continued treatment. Because orlistat may decrease the absorption of fat-soluble vitamins, a standard multiple-vitamin supplement is recommended daily during therapy to prevent abnormalities in vitamin serum concentrations. The potential for severe gastrointestinal discomfort and the modest degree of weight loss may limit the agent's clinical utility. Its long-term safety and effectiveness for weight maintenance, cost-effectiveness of treatment, and overall reduction in obesity-related morbidity and mortality remain to be determined.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / pharmacology*
  • Anti-Obesity Agents / therapeutic use
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Lactones / pharmacology*
  • Lactones / therapeutic use
  • Lipase / antagonists & inhibitors*
  • Obesity / drug therapy
  • Obesity / prevention & control*
  • Orlistat
  • Randomized Controlled Trials as Topic


  • Anti-Obesity Agents
  • Enzyme Inhibitors
  • Lactones
  • Orlistat
  • Lipase